Wednesday, July 8, 2026

biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactati

Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Employees
213
Programs
7
Drugs
14
Patents
72

Quick answer

Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactation Suppressed, NSCLC, Brain Neoplasms, Malignant, Primary. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 72 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3), approved (2), phase 1 (2).

Company snapshot

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical librari

  • 7 active pipeline program(s) linked via ClinicalTrials.gov.
  • 72 US patent(s) indexed to this assignee profile.
  • 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Monte Rosa Therapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Monte Rosa Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 5 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Monte Rosa Therapeutics.

  1. Clinical update

    F106-CT01 — Phase 2

  2. Clinical update

    Vyndaqel 61 mg soft capsules — Approved

  3. Clinical update

    Temozolomide — Approved

  4. Clinical update

    Oral MRT-2359 — Phase 2

  5. Clinical update

    Cabergoline 1 MG — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Monte Rosa Therapeutics?

    Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactation Suppressed, NSCLC, Brain Neoplasms, Malignant, Primary. N

  • Is Monte Rosa Therapeutics publicly traded?

    Yes. Monte Rosa Therapeutics is listed with ticker GLUE on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Monte Rosa Therapeutics develop or market?

    We link 14 drug profile(s) where Monte Rosa Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/monte-rosa-therapeutics#company-drugs.

  • What are the latest developments for Monte Rosa Therapeutics?

    In the last 12 months our linked public records show 7 trial program update(s) and 2 US patent grant(s) tied to this profile.

  • What therapeutic areas does Monte Rosa Therapeutics focus on?

    Monte Rosa Therapeutics focuses on Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactation Suppressed based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
11
Oncology
2
Cardiology
1